Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages

Talking with Kurt von Emster is always interesting. The joint managing partner has been tracking all the financial and development trends that influence his business …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages

This article is available only to Premium subscribers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Let’s make that $1B-plus: Abing­worth gath­ers more cash, this time for its late-stage pok­er game. And we learned that even a biotech nu­clear win­ter has its ad­van­tages

This article is available only to Premium subscribers

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya